Análise do colo femoral de ratas adultas e senis após tratamento com ocitocina.
Carregando...
Data
2016-08-02
Autores
Fernandes, Fernanda [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
Este estudo teve como objetivo analisar e comparar a ação da ocitocina (OT) no metabolismo ósseo de ratas Wistar cíclicas (12 meses) e acíclicas (18 meses/período de periestropausa). Os animais foram distribuídos em quatro grupos: (1) animais com 12 meses que receberam injeção com veículo NaCl (Veh/12); (2) animais com 12 meses que receberam injeção de OT (Ot / 12); (3) animais com 18 meses que receberam injeção com veículo NaCl (Veh/18); (4) animais com 18 meses que receberam injeção de OT (Ot / 18). Cada grupo foi composto por 8 animais. Os animais receberam duas injeções intraperitoneais de NaCl (0,15 M – grupo controle) ou OT (134 ug / kg – grupo tratado) com 12 horas de intervalo. Força, microarquitetura e biomarcadores ósseos [fosfatase alcalina (FAL) e fosfatase ácida resistente ao tartarato (TRAP)] foram analisados. Imunoistoquímica foi realizada para fator de transcrição relacionado com o Runt 2 (RUNX2), osterix (OSX), osteocalcina (OCN), osteopontina (OPN), proteína óssea morfogenética 2 e 4 (BMP-2/4), periostina (PER), esclerostina (ESC) e TRAP. Os animais que receberam OT demonstraram melhora significante na dosagem plasmática: aumento na FAL dos animais de 12 meses (p < 0,0001) e 18 meses (p = 0,0138); diminuição na TRAP dos animais de Ot / 12 (p = 0,0465) e Ot / 18 (p = 0,0045). Houve melhora nos parâmetros biomecânicos: força máxima (N) do grupo Ot / 18 (p = 0,0003); rigidez óssea (x103N/mm) do grupo Ot / 12 (p = 0,0223) e Ot / 18 (p = 0,0145); microarquitetura óssea cortical do grupo Ot / 18 para Ct.Ar (mm2 ) (p = 0,0416) e Ct.Po (%) (p = 0,0102); microarquitetura óssea trabecular para Tb.N (1/mm) (p = 0,0016) e Tb.Sp (p = 0,00010); todos os grupos foram comparados ao seus respectivos controles (Veh/12; Veh/18). Em resumo, os resultados demonstraram que a administração de OT foi eficaz para prevenir a perda de massa óssea em ratas Wistar velhas com hipoestrogenismo, reforçando este agente anabólico como forte alternativa terapêutica para prevenção e tratamento da osteoporose (OP), reduzindo os índices da doença e fraturas osteoporóticas.
This study aimed to analyze and compare the acting of oxytocin (OT) on bone metabolism of cyclic (12 months) and acyclic Wistar rats (18 months/peri-estropause period). Animals were allocated to four groups: (1) animals with 12 months that received vehicle injection NaCl (Veh/12); (2) animals with 12 months that received OT injection (Ot / 12); (3) animals with 18 months that received vehicle (Veh/18) and (4) animals with 18 months that received OT injection (Ot / 18). Eight animals composed each group. The animals received two intraperitoneal injections of NaCl (0.15 M - control group) or OT (134 ug / kg - treated groups) with 12 hours apart. Bone strength, microarchitecture, and biomarkers [alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRAP)] were assessed. Immunohistochemistry was performed for runt-related transcription factor 2 (RUNX2), osterix (OSX), osteocalcin (OCN), osteopontin (OPN), bone morphogenetic protein 2 and 4 (BMP- 2/4), periostin (PER), sclerostin (ESC) and TRAP. Animals that received OT showed significant improvements at plasma assay: increase in the ALP from the animals with 12 months (p < 0.0001) and 18 months (p = 0.0138); decrease in the TRAP from the Ot / 12 (p = 0.0465) and Ot / 18 (p = 0.0045). There was improvements at biomechanical parameters: maximum load (N) from the Ot / 18 (p = 0.0003); bone stiffness (x103N/mm) from the Ot / 12 (p = 0.0223) and Ot / 18 (p = 0.0145); cortical bone microarchitecture from the Ot / 18 to Ct.Ar (mm2 ) (p = 0.0416) and Ct.Po (%) (p = 0.0102); trabecular bone microarchitecture to Tb.N (1/mm) (p = 0.0016) and Tb.Sp. (p = 0.00010); all groups compared to its respective controls (Veh/12; Veh/18). In summary, the results showed the OT administration was effective to prevent the bone loss in old Wistar rats with hypoestrogenism, reforcing this anabolic agent as powerful therapeutic alternative to prevention and treatment for osteoporosis (OP), to reduce the rates of disease and osteoporotic fractures.
This study aimed to analyze and compare the acting of oxytocin (OT) on bone metabolism of cyclic (12 months) and acyclic Wistar rats (18 months/peri-estropause period). Animals were allocated to four groups: (1) animals with 12 months that received vehicle injection NaCl (Veh/12); (2) animals with 12 months that received OT injection (Ot / 12); (3) animals with 18 months that received vehicle (Veh/18) and (4) animals with 18 months that received OT injection (Ot / 18). Eight animals composed each group. The animals received two intraperitoneal injections of NaCl (0.15 M - control group) or OT (134 ug / kg - treated groups) with 12 hours apart. Bone strength, microarchitecture, and biomarkers [alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRAP)] were assessed. Immunohistochemistry was performed for runt-related transcription factor 2 (RUNX2), osterix (OSX), osteocalcin (OCN), osteopontin (OPN), bone morphogenetic protein 2 and 4 (BMP- 2/4), periostin (PER), sclerostin (ESC) and TRAP. Animals that received OT showed significant improvements at plasma assay: increase in the ALP from the animals with 12 months (p < 0.0001) and 18 months (p = 0.0138); decrease in the TRAP from the Ot / 12 (p = 0.0465) and Ot / 18 (p = 0.0045). There was improvements at biomechanical parameters: maximum load (N) from the Ot / 18 (p = 0.0003); bone stiffness (x103N/mm) from the Ot / 12 (p = 0.0223) and Ot / 18 (p = 0.0145); cortical bone microarchitecture from the Ot / 18 to Ct.Ar (mm2 ) (p = 0.0416) and Ct.Po (%) (p = 0.0102); trabecular bone microarchitecture to Tb.N (1/mm) (p = 0.0016) and Tb.Sp. (p = 0.00010); all groups compared to its respective controls (Veh/12; Veh/18). In summary, the results showed the OT administration was effective to prevent the bone loss in old Wistar rats with hypoestrogenism, reforcing this anabolic agent as powerful therapeutic alternative to prevention and treatment for osteoporosis (OP), to reduce the rates of disease and osteoporotic fractures.
Descrição
Palavras-chave
Ocitocina, Envelhecimento, Osso e ossos, Doenças ósseas metabólicas, Oxytocin, Aging, Bone and bones, Metabolic bone diseases